CTCE 9908

Research use only, not for human use.

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.

CTCE-9908 (0-300 μg/mL; for 10 d) inhibits migration and growth in CXCR4-expressing in ovarian cancer cell lines (IGROV, TOV21G and SKOV3). CTCE-9908 inhibits ovarian cancer cell migration to CXCL12. CTCE-9908 does not cause apoptosis or cellular senescence, but induces multinucleation, G2-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE-9908 deregulates DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G2-M phases of the cell cycle.

CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg in FVB/N TgN (MMTV-PyMT)634 male mice.

——

Autophagy

CXCR

——

——

——

1030384-98-5

1927.27

C86H147N27O23

>98% (HPLC)

In Vitro:?H2O : 33.33 mg/mL (17.29 mM)

[H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCCCC(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N[H])CCCCN)C(C)C)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years